It may be feasible to use procalcitonin blood levels to guide antibiotic treatment for adults in hospital with a suspected chest infection. By measuring procalcitonin, an indicator of bacterial infection, clinicians could review their diagnosis earlier.
This reduced antibiotic exposure by 2.5 days with fewer adverse effects and also less mortality. About 14 extra people in every 1,000 who had their management guided by the blood test would be expected to survive the first month, compared with those receiving standard care without this test.
Antibiotics are commonly prescribed pre-emptively for a suspected respiratory infection and may be continued longer than necessary. As blood procalcitonin levels increase in response to bacterial infection, procalcitonin may have potential to guide starting or stopping antibiotics.
This NIHR-funded review adds 18 trials to the growing body of evidence indicating that procalcitonin may help refine the use of antibiotics in select patient groups.
Why was this study needed?
Respiratory infections account for around 10% of the global disease burden and are the most common reason for prescribing antibiotics. Many infections are viral and neither need nor respond to antibiotics. But in practice, it can be hard to distinguish between bacterial and viral infection.
Overprescribing for respiratory infections seems to be a contributor to increasing antibiotic resistance. However, the emergence of resistant bacteria might not be down to overprescribing alone as other factors including unnecessarily long courses of antibiotics might also be partly to blame.
Blood cultures aren’t always accurate or available. A blood marker like procalcitonin that correlates fairly well with bacterial levels may help guide decisions around starting or stopping antibiotics. Numerous trials have investigated it for this use in recent years, in different settings and populations.
In 2015 NICE called for further research in this area. This Cochrane review update adds 18 trials, published in the last five years, looking at procalcitonin-guided treatment in respiratory infections, mostly those treated in hospital settings.
What did this study do?
The review included a total 32 randomised controlled trials, with individual patient data available for 6,708 people in 26 trials. Most trials took place in intensive care or emergency departments, with community-acquired pneumonia the most common diagnosis. Average patient age was 61 years.
Most trials took repeated procalcitonin measures and used similar cut-off levels to guide starting or stopping antibiotics, though a few took one-off measures. Nearly all compared with physician-guided treatment. Only a single trial compared with the inflammatory marker C-reactive protein.
Trials came from 12, mostly high-income countries, though none was UK-based. The participants and assessors were aware of group assignment. However, the outcomes were objective, and so the effect of this bias across trials was thought to be small.
What did it find?
- Procalcitonin-guided treatment gave a 1.4% absolute reduction in risk of death within 30 days. 8.6% of people in the intervention groups died compared with 10% of controls (odds ratio [OR] 0.83, 95% confidence interval [CI] 0.70 to 0.99). This was high-quality evidence from patient data across the 26 trials with similar findings across all settings, though only two studies were in primary care.
- Standard care led to an average of 8.1 days of antibiotic use. There was high-quality evidence that procalcitonin guidance reduced antibiotic exposure by 2.43 days compared with control (95% CI -2.15 to -2.71 days; 26 studies).
- There was no difference between groups in the rate of treatment failure by 30 days (23% intervention vs 25% controls; OR 0.90, 95% CI 0.80 to 1.01; 26 studies). This was as defined by death, worsening infection or complications, or any ongoing respiratory symptoms at follow-up.
- Procalcitonin measurement reduced the number of people experiencing adverse effects from 22.1% to 16.3% (OR 0.68, 95% CI 0.57 to 0.82; moderate evidence from six studies, 3,034 people).
What does current guidance say on this issue?
NICE recommends using C-reactive protein to guide antibiotic prescribing if there is uncertainty around the diagnosis of pneumonia, with a similar position taken by The British Thoracic Society.
NICE diagnostics guidance (2015) covering different assays to measure procalcitonin said the tests had promise, but there was insufficient evidence to recommend their routine use in the NHS. NICE advised further research into the use of procalcitonin to guide antibiotic treatment in people with suspected bacterial infection.
Surviving Sepsis international guidelines (2017) give a weak recommendation that procalcitonin levels may be used to reduce the duration of antimicrobial therapy in critical care patients with sepsis or suspected sepsis.
What are the implications?
These findings indicate that procalcitonin can be used safely to guide the starting and stopping of antibiotic therapy in adults hospitalised with a respiratory infection. Rapid availability of results may enhance the performance of treatment decision tools.
Reducing duration of antibiotics in this population may help reduce the risk to individuals from antibiotic exposure and also may reduce the overall problem of antibiotic resistance.
About three-quarters of all antibiotic prescriptions take place in primary care. It’s less clear whether procalcitonin may be able to guide antibiotic prescription outside of hospital or whether this test would be a good use of resources there. The researchers note that the rates of bacterial infection and mortality were lower in the two primary care studies they identified.
Citation and Funding
Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95-107.
The National Institute for Health Research (NIHR) provided a research grant for this review update.
NICE. Procalcitonin for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay). DG18. London: National Institute for Health and Care Excellence; 2015.
NICE. Pneumonia in adults: diagnosis and management. CG191. London: National Institute for Health and Care Excellence; 2014.
British Thoracic Society. Guidelines for the management of community acquired pneumonia in adults. London: British Thoracic Society; 2009 update.
Rhodes A, Evans L, Alhazzani W, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.
NICE. Antimicrobial stewardship: systems and process for effective antimicrobial medicine use. NG15. London: National Institute for Health and Care Excellence; 2015.
NICE. Antimicrobial stewardship. QS121. London: National Institute for Health and Care Excellence; 2016.
NICE. Respiratory tract infections (self-limiting): prescribing antibiotics. CG69. London: National Institute for Health and Care Excellence; 2008.
NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. CG101. London: National Institute for Health and Care Excellence; 2010.
Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;(10):CD007498.
Produced by the University of Southampton and Bazian on behalf of NIHR through the NIHR Dissemination Centre